title: Factors affecting the benefit of insulin dose intensification in people with Type 2 diabetes: an analysis from the OpT2mise randomized trial.
authors: Department of Endocrinology, City Hospital Hietzing, Vienna, Austria.
authors: I
authors: I
authors: Schütz-Fuhrmann
authors: Medtronic Bakken Research Center, Maastricht, The Netherlands.
authors: J
authors: J
authors: Castañeda
authors: Department of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center, Caen, France.
authors: Y
authors: Y
authors: Reznik
authors: LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
authors: R
authors: R
authors: Aronson
authors: Diabetes Unit, Endocrinology and Nutrition Department, University Hospital Clinic, Barcelona, Spain.
authors: I
authors: I
authors: Conget
authors: Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
authors: S
authors: S
authors: Liabat
authors: Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
authors: S
authors: S
authors: Runzis
authors: Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
authors: S
authors: S
authors: de Portu
authors: Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors: O
authors: O
authors: Cohen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
chemical_list: D006442:Glycated Hemoglobin; D007328:Insulin